bioAffinity Technologies Closes $3.2 Million Public Offering to Support Growth in Lung Disease Diagnostics
bioAffinity Technologies, Inc., a biotechnology company focused on developing noninvasive diagnostic tools for the early detection of lung cancer and other pulmonary diseases, has completed a previously announced public offering of securities that generated gross proceeds of approximately $3.2 million before deducting placement agent fees and other offering-related expenses. The financing marks another important step for the Nasdaq-listed company as it continues to advance its diagnostic platform and expand its commercial and clinical capabilities in the field of respiratory disease detection.
The offering underscores bioAffinity Technologies’ ongoing efforts to strengthen its financial position as it pursues a mission centered on improving the diagnosis of lung disease through accurate, noninvasive testing. For a company operating in a segment of biotechnology where innovation, clinical validation, and market adoption all require substantial capital, the completion of this financing provides fresh resources that can help support strategic priorities ranging from product development and commercialization to broader corporate operations.
Financing Brings in $3.2 Million in Gross Proceeds
According to the company, the public offering consisted of 4,000,000 shares of common stock, each carrying a par value of $0.007 per share, along with the option for certain investors to purchase pre-funded warrants in lieu of common stock. The securities were sold at a purchase price of $0.80 per share of common stock, or $0.793 per pre-funded warrant.
In total, the transaction generated aggregate gross proceeds of $3.2 million for bioAffinity Technologies before accounting for fees payable to the placement agent and other estimated expenses related to the offering. While the net proceeds will be lower after those deductions are made, the financing still represents a meaningful capital infusion for a company of bioAffinity’s size and stage of development.
The structure of the transaction also reflects a common financing mechanism used by public biotechnology companies and other growth-stage issuers. In addition to traditional common stock, the company included pre-funded warrants as an alternative investment vehicle for certain purchasers. These instruments allow investors to secure the right to acquire shares at a later point while providing the issuer with nearly the same economic value as an immediate stock purchase.
Understanding the Pre-Funded Warrants
As part of the offering, investors were given the ability to purchase pre-funded warrants in lieu of common shares. Each pre-funded warrant is exercisable for one share of bioAffinity Technologies common stock. The company said these warrants are immediately exercisable and will remain outstanding until exercised in full.
Pre-funded warrants are often used in public offerings when investors want flexibility in how they hold their economic interest in a company, particularly if they are approaching ownership thresholds or have internal investment restrictions tied to outright stock ownership. Because the exercise price attached to a pre-funded warrant is typically nominal, the instrument functions in many ways like common equity, but with certain structural advantages for the investor.
For bioAffinity Technologies, including pre-funded warrants in the transaction likely broadened the appeal of the offering and enabled the company to complete the financing under terms that could accommodate different investor preferences. From a capital-raising standpoint, these warrants still contribute substantially the same upfront proceeds as a direct sale of common stock, helping the company meet its financing objective.
Closing Marks Completion of Previously Announced Offering
The company had previously announced the terms of the financing, and with the closing now completed, the offering moves from an announced capital markets transaction to a finalized source of funding on the company’s balance sheet. The deal was expected to close on or about June 18, 2026, subject to the satisfaction of customary closing conditions, and bioAffinity has now confirmed that the transaction has closed.
That distinction is important because the completion of a financing transaction is what ultimately converts market interest into usable corporate capital. For biotechnology companies, where cash runway is a central concern for investors and management teams alike, the difference between announcing an offering and closing it can be significant. With the closing now complete, bioAffinity can begin deploying the proceeds toward its operational and strategic needs.
WallachBeth Capital Served as Sole Placement Agent
WallachBeth Capital, LLC acted as the sole placement agent for the offering. Placement agents play a critical role in public and private financings by helping issuers structure the deal, market the securities to potential investors, coordinate order flow, and guide the transaction through the closing process.
For smaller public biotechnology companies in particular, placement agents are often central to accessing the capital markets efficiently. They provide expertise on pricing, investor targeting, and execution at a time when market conditions can be volatile and financing windows may be narrow. In this case, WallachBeth Capital’s role as sole placement agent indicates that it was the lead advisor and intermediary responsible for supporting the company throughout the offering process.
Capital Raise Supports bioAffinity’s Broader Growth Strategy
While the company’s announcement focused primarily on the terms and mechanics of the offering, the financing itself is meaningful in the context of bioAffinity Technologies’ broader corporate strategy. The company is focused on the development and commercialization of noninvasive diagnostic tests aimed at improving the early detection of lung cancer and other pulmonary diseases—an area of considerable medical need and commercial opportunity.
Lung cancer remains one of the deadliest forms of cancer worldwide, in large part because it is often diagnosed at a late stage when treatment options are more limited and outcomes are poorer. Technologies that can improve early detection, reduce diagnostic uncertainty, or offer clinicians more accurate and less invasive ways to assess patients are therefore highly valuable. bioAffinity’s work is positioned within that larger healthcare challenge, and the company’s ability to continue advancing its platform depends heavily on its access to capital.
Biotechnology companies at bioAffinity’s stage typically use proceeds from public offerings to support a range of activities, including research and development, laboratory operations, clinical validation work, commercial rollout, reimbursement initiatives, manufacturing support, hiring, and general corporate purposes. Although the company did not detail a specific allocation of proceeds in the announcement, investors generally view these financings as essential to maintaining momentum across the business while management continues executing on strategic milestones.
Importance of Financing for Emerging Diagnostic Companies
For emerging biotechnology and diagnostic companies, capital raises are not just routine financial events—they are often central milestones that determine how aggressively a company can move forward with product development and market expansion. Unlike mature pharmaceutical companies that may already have multiple approved products generating substantial revenue, smaller diagnostic developers often operate in an environment where research, validation, regulatory activities, and commercialization all require ongoing investment before the business reaches sustainable scale.
That is especially true in the diagnostics space, where proving the value of a test can involve more than simply demonstrating scientific accuracy. Companies must also establish clinical utility, educate physicians, build lab or distribution infrastructure, navigate reimbursement pathways, and persuade health systems or providers to adopt new testing approaches. Each of these steps can require meaningful resources. As a result, offerings like the one completed by bioAffinity Technologies are often critical to ensuring that promising technologies have the financial support necessary to progress.
Offering Conducted Through SEC Registration Process
The securities in the offering were sold pursuant to a registration statement on Form S-1 that bioAffinity Technologies had previously filed with the U.S. Securities and Exchange Commission. The registration statement, identified as File No. 333-296764, was amended and later declared effective by the SEC before the company moved forward with the offering.
Using a registered offering structure allows a public company to sell securities to investors in compliance with federal securities laws while providing the market with the disclosures required under SEC regulations. The filing and effectiveness of an S-1 registration statement are key steps in that process, as they ensure that investors have access to material information about the company, the securities being offered, the associated risks, and the intended use of proceeds.
As is standard in such announcements, bioAffinity also emphasized that the press release itself does not constitute an offer to sell or a solicitation of an offer to buy the securities. Any sale of the securities would be made only through the applicable prospectus materials and only in jurisdictions where the offer and sale are legally permitted under securities laws.
Prospectus Availability and Investor Access
The company noted that the offering was made only by means of a preliminary prospectus and a final prospectus forming part of the registration statement. The final prospectus relating to the offering is expected to be filed with the SEC and made available through the SEC’s website.
Investors seeking additional details about the financing, including the terms of the securities, risk factors, and company disclosures, can review the prospectus materials once filed. Electronic copies of the prospectus, when available, may also be obtained from WallachBeth Capital, which served as placement agent for the transaction.
This emphasis on prospectus availability reflects the regulatory framework governing public offerings in the United States. Prospectuses are designed to provide investors with a detailed account of the issuer’s business, financial position, risk profile, and the specific structure of the offering. For public biotechnology companies, such documents can also offer insight into how management views its market opportunity, capital needs, and development roadmap.
A Modest but Strategic Financing Milestone
At $3.2 million in gross proceeds, the offering is relatively modest by the standards of larger public life sciences financings, but for bioAffinity Technologies it still represents a strategically important event. Smaller biotech and diagnostics companies frequently pursue targeted raises of this size to extend their operating runway, fund key near-term milestones, or support commercialization efforts without taking on excessive debt or waiting for a larger financing window.
In that sense, the transaction should be viewed not only as a capital raise, but as a step in the company’s effort to sustain progress in a competitive and capital-intensive healthcare market. Every financing completed by an emerging biotech company carries implications for its ability to continue advancing its science, expanding its market presence, and moving closer to long-term commercial viability.
For bioAffinity Technologies, a company built around the promise of earlier and less invasive detection of lung cancer and other pulmonary conditions, access to fresh capital is closely tied to its ability to deliver on that mission. With the public offering now closed, the company has added new funds to support its operations and strategic priorities, giving it additional financial flexibility as it continues to pursue growth in the diagnostics market.
As the biotechnology sector continues to reward companies that can pair clinical relevance with operational execution, bioAffinity’s latest financing provides another building block in its corporate journey. The company now moves forward with added capital in hand, seeking to advance its diagnostic ambitions and strengthen its position in the evolving landscape of lung disease detection.
About CyPath® Lung
CyPath® Lung by bioAffinity Technologies is a noninvasive test designed to improve the early detection of lung cancer in patients at high risk for the disease. CyPath® Lung uses advanced flow cytometry and proprietary artificial intelligence (AI) to identify cell populations in patient sputum that indicate malignancy. CyPath® Lung incorporates a fluorescent porphyrin that is preferentially taken up by cancer and cancer-related cells.
In a published clinical trial of high-risk patients, CyPath® Lung demonstrated 92% sensitivity, 87% specificity, 88% accuracy and 99% negative predictive value (NPV) in detecting lung cancer in patients at high risk for the disease who had small indeterminate lung nodules less than 20 millimeters. The high NPV gives physicians greater confidence that a negative result is truly negative, potentially sparing patients from unnecessary invasive and costly procedures. CyPath® Lung is marketed as a Laboratory Developed Test (LDT) and is not intended for use as a sole diagnostic tool and should be considered alongside other clinical findings.
About bioAffinity Technologies, Inc.
bioAffinity Technologies, Inc. addresses the need for noninvasive diagnosis of early-stage cancer and other diseases of the lung and broad-spectrum cancer treatments. The Company’s first product, CyPath® Lung, is a noninvasive test that has shown high sensitivity, specificity and accuracy for the detection of early-stage lung cancer.
CyPath® Lung is marketed as a Laboratory Developed Test (LDT) by Precision Pathology Laboratory Services, a subsidiary of bioAffinity Technologies. LDTs are overseen under the Clinical Laboratory Improvement Amendments (CLIA), which are administered by the Centers for Medicare & Medicaid Services.
